Management of patients with non‐alcoholic steatohepatitis (NASH) in real life


Non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) is a prevalent condition that is associated with the development of cirrhosis and hepatocellular carcinoma and with no approved treatment options except for lifestyle changes. Guidelines have been drafted for the management of NAFLD patients in this setting. Because of the lack of real‐life cohort data, we will focus on practice surveys on the management of patients with NAFLD/NASH, which included primary care practitioners, gastroenterologists/hepatologists and other specialists from various countries. Practice patterns have been collected from interviews with practitioners or reviews of patient’s files. This review discusses the screening, diagnosis and therapeutic management of NAFLD/NASH patients in real life practice, as well as adherence to guidelines.


chart review, diagnosis, monitoring, practice survey, screening, therapeutic management


About Speaker

Lawrence SERFATY

MD, Professor of Hepatology and Chief of the Liver Diseases Department


City: Strasbourg

Institution: Hautepierre Hospital, Strasbourg University

Biography of Lawrence SERFATY

Lawrence Serfaty, MD, is Professor of Hepatology and Chief of the Liver Diseases Department, Hautepierre Hospital, University of Strasbourg, France. Dr Serfaty received his Medical degree from University of Paris-Sud and completed his Medical training at Saint-Antoine Hospital, Paris. Before moving to Strasbourg University in 2017, he was the Viral and Metabolic Liver Unit Head and Associate Professor of Medicine in the Department of Hepatology at Saint-Antoine Hospital. He is also Associate Researcher in the INSERM UMR_S938, University Pierre&Marie Curie, Paris 6, France.

Dr Serfaty began his research career studying viral HCV in the early 1990s and then focused on potential mechanisms of steatosis and its role in fibrogenesis in chronic HCV. He then extended his field of research to non-alcoholic fatty liver disease (NAFLD), by investigating mechanisms of liver injury associated with insulin resistance in obese patients as well as those with HIV-associated lipodystrophy. He is now focusing his research on global epidemiology of NAFLD and mechanisms of fibrogenesis in NASH.

Dr Serfaty has been involved in a number of trials evaluating new anti-HCV direct-acting antivirals or new targeting molecules in NASH. He has published more than 160 indexed papers. He is a member of the French Association for the Study of the Liver (AFEF) and the European Association for the Study of the Liver (EASL).

View more